3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
20
enzalutamide
19
apalutamide
17
Prednisone
13
Androgen Antagonists
13
Abiraterone Acetate
13
Specimen Handling
12
abiraterone
8
Radiotherapy
8
Docetaxel
8
Biopsy
8
darolutamide
7
Nivolumab
7
cabazitaxel
6
Radiosurgery
6
Pluvicto
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
Lutetium-177
5
radium Ra 223 dichloride
4
gallium 68 PSMA-11
4
cabozantinib
4
bicalutamide
4
atezolizumab
4
Surveys and Questionnaires
4
Standard of Care
4
Radiotherapy, Intensity-Modulated
4
Radiation
4
Lutetium
4
pembrolizumab
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Serotonin 5-HT3 Receptor Antagonists
×
30 days
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled